drugset / Trial / NCT01598025

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

NCT01598025

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Approximately 30% of patients who are candidates for bone marrow transplants do not have an HLA-matched, or close to matched, donor available. For this reason, doctors have been testing ways to make transplants from HLA-partially matched donors as safe and effective as transplants from HLA-matched donors. This study is being done to test the safety and the treatment results of a specific kind of transplant. In this transplant, blood from two donors will be used. Each donor will share one half of your HLA type. Blood from both donors will be transplanted at the same time.

Timeline

Start
2012-05-02
Primary completion
2017-10-16
Completion
2017-10-16

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic Intravenous
Background Fludarabine Small molecule 25 mg/m2 Intravenous
Background Melphalan Small molecule 70 mg/m2 Intravenous
Background Thiotepa Other / unclassified 5 mg/kg Intravenous
Background Thiotepa Other / unclassified 10 mg/kg Intravenous